COVID-19 search strategies in PharmaPendium: Focus on DMPK and DDIs
About this talk
Many already approved drugs are currently being tested (repurposed) for prevention and treatment of COVID-19 infections and symptoms. To maximize repurposing and treatments success, you need to be fully informed on all regulatory DMPK, efficacy and drug safety data available on EMA and FDA approved drugs.
Elsevier’s PharmaPendium provides access to full text searchable FDA/EMA drug approval Documents, manually extracted data, expert taxonomies and prediction tools. Thereby it is ideally positioned to support COVID-19 repurposing and treatments effort.
In this webinar, PharmaPendium product manager Thomas Vargues and senior marketing manager drug safety Marnix Wieffer will show various PharmaPendium search strategies that are currently being used by pharmaceutical and healthcare customers.
For this webinar they will focus on DMPK and DDI risk prediction workflows. For example:
1.How does patient complications influence therapeutic PK profile and exposure?
2. What DDIs can I expect now I am creating uncommon drug combinations?
3.How to use Pharmacokinetic data to model exposure in COVID-19 patients?
Getting answers to these critical questions can support drug repurposing efforts and reduce risk for patients.